The posters below do not represent all posters presented at the conference; they include only those for which presenters provided a PDF for online viewing.
Click on the image to view the entire poster.
ACTHIV ChangeMakers 2024-25: Clinicians Applying an Adaptive Leadership Framework to Improve HIV Care
ACTHIV ChangeMakers 2024-25: Optimizing Bicillin Administration for Syphilis Treatment in the Carceral Setting
Analyzing Knowledge Status and HIV Linkage to Care: Insights From America’s HIV Epidemic Analysis Dashboard (AHEAD) National Database
Monitoring for HBV Reactivation in PWH Following Antiretroviral Switch to Cabotegravir/Rilpivirine
INCREASE PREP UTILIZATION, AWARENESS,AND EDUCATION AMONG UNDERSERVEDPOPULATIONS IN DALLAS COUNTY
Double IRIS in HIV/AIDS: The Intersection of Immune Reconstitution and Health Disparities
A Mixed-Methods Study of Rapid ART in People Living with Advanced HIV in the Rio Grande Valley
INCREASE PREP UTILIZATION, AWARENESS,AND EDUCATION AMONG UNDERSERVEDPOPULATIONS IN DALLAS COUNTY
Double IRIS in HIV/AIDS: The Intersection of Immune Reconstitution and Health Disparities
HIGH LEVELS OF TREATMENT SUCCESS SEEN WITH COMBINED USE OF TESAMORELIN AND GLP1-RAs IN PEOPLE WITH HIV
The Impact of a Fellow-Led Educational Presentation on Trainees’ Knowledge and Interest in HIV Medicine and/or Infectious Diseases
At the Heart of Healing: Social Work’s Impact in Integrated HIV Care Model
Lessons from Having a Dedicated Medical Assistant for Implementing Long-Acting ART at a Hospital-Based Clinic
Pregnancy Related Outcomes Between INSTI and Non-INSTI ART Regimens in an Urban Hospital Ryan White Clinic
Examining Low Level Viremia Based on Body Mass Index in Injectable Cabotegravir/Rilpivirine
Anal Cancer Screening in a Population of PLWH in an Urban Underserved FQHC Residency Clinic Network: Gaps and Proposal for Increasing Screening
An enabling technology-based specialty pharmaceutical company with focus on long-acting injectables (LAIs)
Using Contingency Management to Increase Uptake of Long-Acting Injectable PrEP in People Who Use Drugs: Harm Reduction & Street Medicine in Detroit
“Harm Reduction Angels”: Linking Veterans Who Inject Drugs to Key Resources
Evaluating Impact of a Pharmacist-Led HIV PrEP Clinic for Veterans in Outpatient Substance Use Treatment
The Case for Care Coordination through the Lens of Adaptive Leadership
ACTHIV ChangeMakers: An Artistic Expression of Wellness in the Ponce Clinic Community
Evaluating Impact of a Pharmacist-Led HIV PrEP Clinic for Veterans in Outpatient Substance Use Treatment
Language matters when communicating about HIV. Survey of 100 PLH at the monthly updates hosted by the San Diego HIV Consortium (SDHIVConsortium.org)
Grassroots Initiative to Address Mental Health Needs Among People Living with HIV (PLH) in San Diego, CA, USA
Trends in HIV-1 Drug Resistance in the United States: 2019-2024
Overlap of Pre-exposure Prophylaxis (PrEP) Landscape and Substance Use in the United States (US)
High Real-World Adherence With Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Among People With HIV (PWH) in the United States (US)
PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Change in Healthcare Professional’s Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study
PAIRED – PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States (US)
Interim demographic, clinical characteristics, and effectiveness in the REGAL cohort: a REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV
Treatment-Emergent Integrase Strand Transfer Inhibitor (INSTI) Resistance-Associated Mutations Among People With HIV-1 Treated With Dolutegravir (DTG) + Lamivudine (3TC) With Pre-existing M184V/I From Real-world and Interventional Studies
Perceived Impact of an Electronic Patient-Reported Outcomes Platform (MyPRO) on Patient-Provider Interactions Among Women Living With and Without HIV in a Community Health Clinic Serving Racialized Women in Toronto, Canada
Enhanced Patient Experiences After 12 Months Switch to Cabotegravir and Rilpivirine Long-Acting Therapy: High Treatment Satisfaction, Strong Preference, and Reduced Treatment-Related Challenges Across Gender, Race, and Age in the Real-world BEYOND Study
High and Consistent Virologic Suppression Rates With Similar Adherence Were Observed Across Demographic Subgroups (Gender, Age, Race, BMI) Following 12 Months Switch of Cabotegravir and Rilpivirine Long-Acting Therapy in the Real-world BEYOND Study
Copyright © American Academy of CME, Inc. 2026
Website designed by Netlynx Inc
